Literature DB >> 30536379

Long noncoding RNA GACAT3 promotes glioma progression by sponging miR-135a.

Jing Wang1, Ming Zhang1, Weifeng Lu1.   

Abstract

The long noncoding RNA (lncRNA) gastric cancer associated transcript 3 (GACAT3) has been reported to play important roles in human tumorigenesis. However, its expression pattern, functions, and underlying mechanism in glioma remain unclear. In the present study, we showed that GACAT3 is upregulated in glioma tissues and cell lines. Through online databases, luciferase reporter assays and RNA immunoprecipitation (RIP) assays, we determined that GACAT3 acts as a competing endogenous RNA (ceRNA) for microRNA (miR)-135a, which was downregulated and performed as a tumor inhibitor in glioma. Further, nicotinamide phosphoribosyl transferase (NAMPT) was confirmed as a target gene of miR-135a by a series of gain- and loss-of-function assays. Overall, the present study was the first to show that GACAT3 regulates the expression of NAMPT to promote glioma progression by sponging miR-135a. These findings provide a promising therapy strategy for glioma.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  GACAT3; LncRNA; ceRNA; glioma; miR-135a

Mesh:

Substances:

Year:  2018        PMID: 30536379     DOI: 10.1002/jcp.27946

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  14 in total

1.  LncRNA ROR is involved in cerebral hypoxia/reoxygenation-induced injury in PC12 cells via regulating miR-135a-5p/ROCK1/2.

Authors:  Hong Chen; Xiaoming Li
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

2.  The lncRNA-DLEU2/miR-186-5p/PDK3 axis promotes the progress of glioma cells.

Authors:  Zuochang Xie; Xiaojian Li; Hua Chen; Ailiang Zeng; Yan Shi; Yong Tang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

3.  NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.

Authors:  Xiao-Qin Li; Jing Lei; Lin-Hong Mao; Qing-Liang Wang; Feng Xu; Tao Ran; Zhi-Hang Zhou; Song He
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

4.  Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL.

Authors:  Jian Yan; Chunhua Xu; Youping Li; Bin Tang; Shenhao Xie; Tao Hong; Erming Zeng
Journal:  J Cell Mol Med       Date:  2019-06-26       Impact factor: 5.310

Review 5.  MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy.

Authors:  Zhe Cao; Jiangdong Qiu; Gang Yang; Yueze Liu; Wenhao Luo; Lei You; Lianfang Zheng; Taiping Zhang
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

6.  Transforming Growth Factor-Beta-Regulated LncRNA-MUF Promotes Invasion by Modulating the miR-34a Snail1 Axis in Glioblastoma Multiforme.

Authors:  Bakhya Shree; Shraddha Tripathi; Vivek Sharma
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 7.  Advances in NAD-Lowering Agents for Cancer Treatment.

Authors:  Moustafa S Ghanem; Fiammetta Monacelli; Alessio Nencioni
Journal:  Nutrients       Date:  2021-05-14       Impact factor: 5.717

Review 8.  Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment.

Authors:  Jie Qin; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

9.  Silencing lncRNA ZFAS1 or elevated microRNA-135a represses proliferation, migration, invasion and resistance to apoptosis of osteosarcoma cells.

Authors:  Zilong Zhao; Xiafei Lin; Yunhui Tong; Wenxia Li
Journal:  Cancer Cell Int       Date:  2019-12-03       Impact factor: 5.722

10.  LncRNAs GACAT3 and LINC00152 regulate each other through miR-103 and are associated with clinicopathological characteristics in colorectal cancer.

Authors:  Shazhou Ye; Yicong Lu; Yuqing Ru; Xiaoyue Wu; Ming Zhao; Jiayi Chen; Mingjun Xu; Qin Huang; Yibo Wang; Shanping Shi; Shizhong Bu; Yang Xi
Journal:  J Clin Lab Anal       Date:  2020-05-27       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.